{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:46:15Z","timestamp":1792089975822,"version":"4.4.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The purpose of this study is to characterize patient-reported taste disturbances, recalled symptom course, nutritional changes, and quality of life in patients with relapsed\/refractory multiple myeloma treated with talquetamab. This single-center cross-sectional study combined taste-strip testing with a study-specific questionnaire, EORTC QLQ-C30, and PHQ-4 in 32 patients. Analyses used recorded aggregate correct-identification counts without a normative hypogeusia classification. Symptom timing and changes since treatment initiation were recalled at one assessment. All patients reported taste disturbances during therapy. The median identification count was 2.5 (interquartile range 0.75\u20137.25); eight patients had no correct identifications. Twenty-three (71.9%) described onset within 14 days. Current appetite reduction was reported by 20 patients (62.5%), whose mean identification count was lower than that of the other 12 patients (2.45 versus 7.83; mean difference \u2212\u20095.38, 95% confidence interval \u2212\u20098.20 to \u2212\u20092.57;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0006). Sixteen patients (50.0%) reported directional weight loss, with a median loss of 4.5 kg. Ten (31.3%) had considered stopping talquetamab; seven explicitly cited taste disturbance. Mean global health status was 50.5\/100 and correlated with identification count (\n                    <jats:italic>r<\/jats:italic>\n                    \u2009=\u20090.406;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.021). Taste disturbances co-occurred with substantial nutritional concerns. Lower taste-identification counts were associated with current appetite reduction and lower global health status. The findings support attention to taste-related burden but do not establish causality, sustained recovery, or effects on adherence. Prospective evaluations of supportive care are needed.\n                  <\/jats:p>","DOI":"10.1007\/s00520-026-11288-4","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:40:30Z","timestamp":1791236430000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gustatory dysfunction under talquetamab therapy in multiple myeloma: a cross-sectional study of patient-reported course, nutritional changes, and quality of life"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8760-3931","authenticated-orcid":false,"given":"Anna","family":"Fleischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Roll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Panther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick-Pascal","family":"Strunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie-Katrin","family":"Kadel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Gesierich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Mersi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Waldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kort\u00fcm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad","family":"Maatouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Rasche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"11288_CR1","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG et al (2022) Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med 387:2232\u20132244. https:\/\/doi.org\/10.1056\/NEJMoa2204591","journal-title":"N Engl J Med"},{"key":"11288_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-08233-0","volume":"32","author":"AMGA Laheij","year":"2024","unstructured":"Laheij AMGA, van de Donk NWCJ (2024) Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab. Support Care Cancer 32:20. https:\/\/doi.org\/10.1007\/s00520-023-08233-0","journal-title":"Support Care Cancer"},{"key":"11288_CR3","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/jha2.971","volume":"5","author":"S Naqvi","year":"2024","unstructured":"Naqvi S, Shrestha A, Alzubi M et al (2024) Weight loss and dysgeusia in relapsed\/refractory multiple myeloma patients treated with talquetamab. EJHaem 5:789\u2013792. https:\/\/doi.org\/10.1002\/jha2.971","journal-title":"EJHaem"},{"key":"11288_CR4","doi-asserted-by":"publisher","first-page":"12897","DOI":"10.1007\/s00432-023-05137-8","volume":"149","author":"A Fleischer","year":"2023","unstructured":"Fleischer A, Zapf L, Allgaier J et al (2023) A patient survey indicates quality of life and progression-free survival as equally important outcome measures in multiple myeloma clinical trials. J Cancer Res Clin Oncol 149:12897\u201312902. https:\/\/doi.org\/10.1007\/s00432-023-05137-8","journal-title":"J Cancer Res Clin Oncol"},{"key":"11288_CR5","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1007\/s00520-026-10863-z","volume":"34","author":"A Fleischer","year":"2026","unstructured":"Fleischer A, Roll M, Panther F et al (2026) Supportive care for talquetamab-related dysgeusia in multiple myeloma: mixed-methods evidence, nutrition-focused flowchart, and digital companion concept. Support Care Cancer 34:668. https:\/\/doi.org\/10.1007\/s00520-026-10863-z","journal-title":"Support Care Cancer"},{"key":"11288_CR6","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1007\/s00520-020-05717-1","volume":"29","author":"K Drareni","year":"2021","unstructured":"Drareni K, Bensafi M, Giboreau A, Dougkas A (2021) Chemotherapy-induced taste and smell changes influence food perception in cancer patients. Support Care Cancer 29:2125\u20132132. https:\/\/doi.org\/10.1007\/s00520-020-05717-1","journal-title":"Support Care Cancer"},{"key":"11288_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71401","volume":"14","author":"A Fleischer","year":"2025","unstructured":"Fleischer A, Roll M, Frenking JH et al (2025) Talquetamab-related dysgeusia in multiple myeloma compared to BCMA-targeted bispecifics and high-dose melphalan. Cancer Med 14:e71401. https:\/\/doi.org\/10.1002\/cam4.71401","journal-title":"Cancer Med"},{"key":"11288_CR8","first-page":"2","volume":"41","author":"C Mueller","year":"2003","unstructured":"Mueller C, Kallert S, Renner B, Stiassny K, Temmel AFP, Hummel T, Kobal G (2003) Quantitative assessment of gustatory function in a clinical context using impregnated \u201ctaste strips.\u201d Rhinology 41:2\u20136","journal-title":"Rhinology"},{"key":"11288_CR9","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s00415-009-0088-y","volume":"256","author":"BN Landis","year":"2009","unstructured":"Landis BN, Welge-Luessen A, Br\u00e4merson A, Bende M, Mueller CA, Nordin S, Hummel T (2009) \u201cTaste strips\u201d\u2014a rapid, lateralized, gustatory bedside identification test based on impregnated filter papers. J Neurol 256:242\u2013248. https:\/\/doi.org\/10.1007\/s00415-009-0088-y","journal-title":"J Neurol"},{"key":"11288_CR10","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1177\/000348941112000602","volume":"120","author":"CA Mueller","year":"2011","unstructured":"Mueller CA, Pintscher K, Renner B (2011) Clinical test of gustatory function including umami taste. Ann Otol Rhinol Laryngol 120:358\u2013362. https:\/\/doi.org\/10.1177\/000348941112000602","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"11288_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365\u2013376. https:\/\/doi.org\/10.1093\/jnci\/85.5.365","journal-title":"J Natl Cancer Inst"},{"key":"11288_CR12","unstructured":"Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group (2001) The EORTC QLQ-C30 scoring manual, 3rd edn. European Organisation for Research and Treatment of Cancer, Brussels, p 86"},{"key":"11288_CR13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jad.2009.06.019","volume":"122","author":"B L\u00f6we","year":"2010","unstructured":"L\u00f6we B, Wahl I, Rose M, Spitzer C, Glaesmer H, Wingenfeld K, Schneider A, Br\u00e4hler E (2010) A 4-item measure of depression and anxiety: validation and standardization of the Patient Health Questionnaire-4 (PHQ-4) in the general population. J Affect Disord 122:86\u201395. https:\/\/doi.org\/10.1016\/j.jad.2009.06.019","journal-title":"J Affect Disord"},{"key":"11288_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/nu18142393","volume":"18","author":"A Fleischer","year":"2026","unstructured":"Fleischer A (2026) Natural taste modulators and microbiome-aware nutritional support for immunotherapy-associated dysgeusia: a translational perspective for precision supportive cancer care. Nutrients 18:2393. https:\/\/doi.org\/10.3390\/nu18142393","journal-title":"Nutrients"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11288-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11288-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11288-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:48:19Z","timestamp":1792086499000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11288-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":14,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["11288"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-11288-4","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"26 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee of the University of W\u00fcrzburg (AZ 119\/22) and was conducted in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No identifying participant information is included in the manuscript, figures, or Online Resource\n                      \n                      .","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AF received honoraria from GSK, BMS and Janssen. JW: Consultancy for Johnson&Johnson, Sanofi, Takeda, Pfizer, Oncopeptides, Skyline Dx; Honoraria from GSK, Johnson&Johnson, Pfizer and Beigene; Research support from BMS. LR received honoraria from Amgen, BMS, GSK, Janssen, Sanofi, and Pfizer and research funding from BMS. KMK received Honoraria from Abbvie, Beigene, BMS, GSK, Johnson&Johnson, Menarini, Novartis, Pfizer and Sanofi. AG served as consultant and\/or has received honoraria or travel costs from Allmiral, Amgen, Bristol-Myers Squibb, Immunocore, MSD Sharp & Dohme; Novartis, Pierre Fabre Pharmaceuticals, Pfizer, Regeneron, Roche and Sanofi Genzyme, outside the submitted work.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1059"}}